Arie Belldegrun (Photo: Jeff Rumans for Endpoints News)
April 12, 2020 01:57 PM EDT
R&D

Judge slaps en­hanced dam­ages on Gilead/Kite for ‘will­ful’ patent vi­o­la­tion, boost­ing award to a block­buster $1.2B — with the me­ter run­ning

John Carroll

Editor & Founder

The Gilead/Kite team has suf­fered the lat­est in a se­ries of set­backs in its war with Bris­tol My­ers Squibb sub­sidiary Juno and Memo­r­i­al Sloan Ket­ter­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times